Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.43 |
| ▸ | TSHR | P16473 | 8/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871698 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| Hydrochloric Acid SCHEMBL21879618 | 0.97 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL8960736 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL30785388 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL3971917 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL2361143 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL6403160 | 0.79 | CYP3A4 (0.46) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL30181379 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL8282372 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRPIK3CATP53 | |
| SCHEMBL900037 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CYP3A4TSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707773-A | Preparation method and application of maleimide structure-containing compound | 中国农业大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119707773-A | Preparation method and application of maleimide structure-containing compound | 中国农业大学 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-4757081-A | Agriculture, horticulture | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0239391-A2 | 1,2,6-triphenyl-4(1H)-pyridinone and pyridinethione derivatives, production and uses thereof | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1987-09-30 | — | — | EP | disclosed |
| EP-0034945-B1 | N-PHENYLPYRAZOLE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1985-08-07 | — | — | EP | disclosed |
| US-4496390-A | WEED-CONTRTOLLING HERBICIDES | MAY & BAKER LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0062659-A4 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES. | FMC CORP (US) | 1983-01-14 | — | — | EP | disclosed |
| EP-0062659-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC Corporation (US) | 1982-10-20 | — | — | EP | disclosed |
| US-4339457-A | OF CYCLOPROPANECARBOXYLIC ACIDS, INSECTICIDES, MITICIDES | FMC CORPORATION (US) | 1982-07-13 | — | — | US | disclosed |
| WO-1982001368-A1 | 3-(PYRROL-1-YL)PHENYLMETHYL ESTERS AND INTERMEDIATES | FMC CORP (US) | 1982-04-29 | — | — | WO | disclosed |
| EP-0034945-A2 | N-phenylpyrazole derivatives | MAY & BAKER LIMITED (GB) | 1981-09-02 | — | — | EP | disclosed |
| US-4238505-A | HIGH TOXICITY | FMC CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | EGFR, ERBB2, ERBB4 | ALDH1A1 3390/4885CYP3A4 3732/4885TSHR 2223/4885 |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | EGFR, ERBB2, ERBB4 | ALDH1A1 3390/4885CYP3A4 3732/4885TSHR 2223/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | ALDH1A1 1802/4885CYP3A4 1911/4885TSHR 274/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | ALDH1A1 1802/4885CYP3A4 1911/4885TSHR 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.